NeoGenomics, Inc. (NASDAQ:NEO) Receives $19.50 Consensus Price Target from Analysts

NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) has earned an average rating of "Moderate Buy" from the ten brokerages that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $19.50.

A number of analysts have commented on the stock. The Goldman Sachs Group upped their price target on shares of NeoGenomics from $17.00 to $19.00 and gave the company a "buy" rating in a research report on Thursday, February 22nd. William Blair reissued an "outperform" rating on shares of NeoGenomics in a research report on Wednesday, February 21st. BTIG Research reduced their price target on shares of NeoGenomics from $25.00 to $21.00 and set a "buy" rating for the company in a research report on Friday, December 29th. TD Cowen decreased their target price on NeoGenomics from $22.00 to $19.00 and set an "outperform" rating for the company in a research report on Friday, December 29th. Finally, Needham & Company LLC upped their price target on shares of NeoGenomics from $21.00 to $24.00 and gave the company a "buy" rating in a research note on Wednesday, February 21st.

NeoGenomics Trading Down 1.7 %

Shares of NeoGenomics stock traded down $0.24 during midday trading on Friday, reaching $13.53. The company had a trading volume of 771,486 shares, compared to its average volume of 902,447. The stock has a fifty day moving average price of $15.13 and a 200 day moving average price of $15.82. NeoGenomics has a fifty-two week low of $11.03 and a fifty-two week high of $21.22. The firm has a market cap of $1.73 billion, a PE ratio of -19.43 and a beta of 1.10. The company has a debt-to-equity ratio of 0.57, a current ratio of 6.20 and a quick ratio of 5.95.

NeoGenomics (NASDAQ:NEO - Get Free Report) last issued its quarterly earnings results on Tuesday, February 20th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.05. NeoGenomics had a negative net margin of 14.87% and a negative return on equity of 4.13%. The firm had revenue of $155.55 million for the quarter, compared to the consensus estimate of $152.90 million. On average, equities analysts anticipate that NeoGenomics will post -0.2 earnings per share for the current year.

Insider Transactions at NeoGenomics

In other news, General Counsel Alicia C. Olivo sold 2,587 shares of the firm's stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $14.96, for a total value of $38,701.52. Following the transaction, the general counsel now owns 34,866 shares in the company, valued at $521,595.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.30% of the company's stock.

Institutional Trading of NeoGenomics

Institutional investors have recently modified their holdings of the company. Citigroup Inc. boosted its stake in shares of NeoGenomics by 245.3% during the 1st quarter. Citigroup Inc. now owns 370,223 shares of the medical research company's stock valued at $4,498,000 after purchasing an additional 263,007 shares in the last quarter. AlphaCrest Capital Management LLC purchased a new position in shares of NeoGenomics in the 1st quarter valued at approximately $201,000. MetLife Investment Management LLC grew its stake in NeoGenomics by 57.4% in the first quarter. MetLife Investment Management LLC now owns 61,509 shares of the medical research company's stock worth $747,000 after purchasing an additional 22,424 shares during the period. Rhumbline Advisers grew its stake in NeoGenomics by 6.9% in the first quarter. Rhumbline Advisers now owns 302,061 shares of the medical research company's stock worth $3,670,000 after purchasing an additional 19,588 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in NeoGenomics by 14.1% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 106,143 shares of the medical research company's stock worth $1,290,000 after purchasing an additional 13,087 shares in the last quarter. 98.50% of the stock is currently owned by hedge funds and other institutional investors.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.